Molecure S.A.

WSE:MOC Lagerbericht

Marktkapitalisierung: zł173.4m

Molecure Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Marcin Szumowski

Geschäftsführender

zł473.2k

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführerno data
Eigentum des Geschäftsführers0.7%
Durchschnittliche Amtszeit des Managements3.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder2.8yrs

Jüngste Management Updates

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04
OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24
Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02
Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Geschäftsführer

Marcin Szumowski

no data

Amtszeit

zł473,205

Vergütung

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Marcin Szumowski
Co-Founderno datazł473.21k0.70%
PLN 1.2m
Slawomir Broniarek
CFO & Member of the Management Boardno datazł421.09k0.20%
PLN 355.4k
Zbigniew Zaslona
Chief Scientific Officer & Member of Management Board2.8yrszł473.21k0.11%
PLN 194.6k
Agnieszka Rajczuk-Szczepanska
Member of Management Board & HR Director4.8yrszł348.41k0.034%
PLN 59.7k
Adam Golebiowski
Co-Founder & VP of Research Chemistry12.8yrszł500.00k3.01%
PLN 5.2m
Jacek Olczak
Co-Founder & Head of Medicinal Chemistryno datakeine Datenkeine Daten
Piotr Iwanowski
Chief Medical Officer & Member of Management Boardless than a yearkeine Datenkeine Daten
Magdalena Tyszkiewicz
Head of CMC4.8yrskeine Datenkeine Daten
Marta Borkowska
Director of the Management Board Office2.8yrskeine Datenkeine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: MOCDas Führungsteam des Unternehmens gilt als erfahren (3.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Luke O'Neill
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Bart Lambrecht
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Tomasz Piec
Vice Chairman of the Supervisory Board4.8yrszł133.62kkeine Daten
Douglas Hay
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Paul Van Der Horst
Independent Chairman of the Supervisory Board2.8yrszł132.99k0.059%
PLN 103.0k
Nancy Van Osselaer
Independent Member of the Supervisory Board2.8yrszł124.22kkeine Daten
Agnieszka Motyl
Member of the Supervisory Board1.3yrszł44.45kkeine Daten
Pawel Trawkowski
Independent Member of the Supervisory Board2.4yrszł124.22kkeine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: MOCDie Vorstandsmitglieder gelten nicht als erfahren ( 2.8 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.